evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
350
transarterial infusion
SUN YAT-SEN University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGOS
overall survival
Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months
ORR
object response rate
Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months
PFS
progression-free survival
Time frame: From date of randomization until the date of progress from any cause, assessed up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.